FRA
MBOT icon

Front Row Advisors’s Microbot Medical MBOT Stock Holding History

Front Row Advisors’s Portfolio MBOT Stock Details MBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1
Closed -$1 – 704
2024
Q2 		$1 Hold
1
– – ﹤0.01% 942
2024
Q1 		$1 Hold
1
– – ﹤0.01% 928
2023
Q4 		$2 Hold
1
– – ﹤0.01% 473
2023
Q3 		$1 Hold
1
– – ﹤0.01% 919
2023
Q2 		$0 Hold
1
– – ﹤0.01% 922
2023
Q1 		$0 Buy
+1
New +$3 ﹤0.01% 932

Other funds holding MBOT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $100M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TFS
Thoroughbred Financial Services Brentwood, Tennessee $1.67B AUM 37.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Front Row Advisors's MBOT Position: Q3 2024 in Review

Front Row Advisors sold out of Microbot Medical (MBOT) in Q3 2024, closing a stake of 1 share — an estimated $1 sold.

Front Row Advisors first reported a position in MBOT in Q1 2023 and held it in 6 quarters. The position peaked at $2 in Q4 2023. 25 funds tracked by Wall St. Rank hold MBOT as of Q3 2024.

  • Front Row Advisors reported no remaining Microbot Medical position as of Q3 2024 after selling out during the quarter.
  • Front Row Advisors sold 1 Microbot Medical share in Q3 2024, an estimated $1.
  • Front Row Advisors first reported a position in Microbot Medical in Q1 2023 and held it in 6 quarters.
  • Front Row Advisors's Microbot Medical position peaked at $2 in Q4 2023.
  • 25 funds tracked by Wall St. Rank held Microbot Medical as of Q3 2024.

Based on Front Row Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.